News and Trends 9 Oct 2018 Hormone Therapy for Inherited Hormonal Disorder Fails at Phase III A European Phase III trial has become a major stress for British biotech Diurnal. Its specially designed hormone therapy was no better than conventional therapies in treating an inherited hormonal disorder. Congenital adrenal hyperplasia is a rare genetic condition where patients lack crucial enzymes for making hormones. The most common form lacks 21-hydroxylase, the enzyme […] October 9, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […] October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2018 Algorithm Proves Better Than Humans at Controlling Blood Sugar in Type 1 Diabetes A clinical trial has shown that letting an algorithm decide the amount of insulin a person with type 1 diabetes needs can help keep blood sugar levels under control. The algorithm, being developed at the University of Cambridge, is able to predict how much insulin is needed at each point in time based on the […] October 3, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 16 Sep 2018 Meet the Entrepreneurs Doing Biotech from Shipping Containers in London Creative biotech startups are brewing inside a shipping container park that offers affordable research space for biologists, engineers and designers working together. The space, called Open Cell, will be opening its doors to the public this week for the London Design Festival. Chip boards made using potato waste, construction materials made with fungi and crystals […] September 16, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 11 Sep 2018 How To Break Into The Crowded Immuno-Oncology Space The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in this crowded field, many companies struggle to make therapies that not only are effective and safe, but that can also be scaled-up, manufactured and commercialized. Helen Tayton-Martin, Chief Business Officer at the biotech company Adaptimmune, shares her advice on how […] September 11, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 4 Sep 2018 Semi-Artificial Photosynthesis Method Produces Fuel More Efficiently Than Nature Scientists at the University of Cambridge have developed a new photosynthesis method that combines biological and synthetic components to produce hydrogen using sunlight as the only source of energy. “Natural photosynthesis has evolved to store solar energy and to reduce the greenhouse gas carbon dioxide into sugars, but this process is not very energy […] September 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2018 Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets Evox Therapeutics has raised £35.5M (€39.4M) in a Series B fundraising that has been backed, among others, by the venture arm of Google’s parent company. A spin-out from the University of Oxford and the Karolinska Institute, Evox Therapeutics has raised a large round that will fund the development of its drug delivery technology to […] September 3, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 3 Sep 2018 Moving from Big Pharma to Biotech – Insights from Two Biotech CEOs According to John LaMattina in Forbes last year, more and more senior scientific executives are moving from pharma to small biotechs or startup initiatives. While the jury is out on whether this observation reflects a real trend or not, we at Labiotech are keen to learn about what drives people to make such a move! […] September 3, 2018 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2018 Novo Nordisk Buys British ‘Smart’ Insulin Diabetes Biotech in deal worth €702M Novo Nordisk acquired the UK biotech Ziylo, which develops glucose-responsive insulin treatments for diabetes that act in response to changes in blood sugar levels. The Danish big-pharma, which is already a big player in the diabetes space, acquired the full rights to Ziylo’s technology in a deal worth up to €702M ($800M). Novo will use the […] August 17, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 Aug 2018 London Biotech Gets Positive Phase III Results for its Monthly HIV Treatment ViiV Healthcare has shown its monthly two-drug HIV treatment works as well as a daily three-drug treatment, which could help reduce the total number of drugs taken by patients. In a Phase III trial that recruited 618 people, London biotech ViiV Healthcare aimed to see if adult HIV-positive patients who had been taking daily antiretroviral […] August 15, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Aug 2018 Orchard Therapeutics Raises €132M to Develop Gene Therapies Orchard Therapeutics raised $150M (€132M) in Series C financing to bring its gene therapies from clinical testing to regulatory approval. The British biotech will use the funding to develop its most advanced clinical programs, which aim to treat rare inherited metabolic and immune system diseases. The news follows Orchard’s acquisition of GSK’s entire gene therapy […] August 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2018 UK Biotech Raises €73M to Target DNA Repair in Treating Cancer Artios Pharma completed a €73M (£65M) Series B financing round to develop cancer treatments that target DNA repair mechanisms. Cancer occurs when cells in part of the body start dividing uncontrollably as a result of damaged or mutated DNA. In collaboration with Cancer Research UK, Artios Pharma is developing cancer treatments that inhibit proteins involved […] August 10, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email